tlx250,girentuximab
esteve,prometheus,telix pharmaceuticals,heidelberg pharmaceuticals
['rcc,(-irccs),(-srcc),(-urcc)', 'zircon', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'tlx250', 'girentuximab', 'imab ']
lba presented @ 14:00 pst #gu23 zircon - ph 3 study of 89zr-dfo-girentuximab for pet/ct imaging of ccrcc (n=284) prim obj - sensitivity for ccrcc in indeterminate rms: 86% (95%ci 80-90); specificity: 87% (95%ci 79-92) sec obj - sensitivity for ccrcc in ct1a 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday